Bayer Looks To Turn Aleve Around Following Negative Media Hit

 
• By The Tan Sheet

Press coverage of a halted NIH study that called into question the cardiovascular safety of naproxen will cause an approximate $30 mil. decline in first-quarter U.S. Aleve sales, according to Bayer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet